Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + IBI310 in advanced ICC
NCT04634058Phase 2Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, IBI310 in intrahepatic cholangiocarcinoma (ICC), sponsored by Zhongshan Hospital, Fudan University. Started Mar 2021; status: active, not recruiting.
02
Drugs
adebrelimabIBI310
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04634058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04634058.